Reach Us +1-218-451-2974


A Major Early Driver Of Tauopathy And Neurodegeneration That Is Blocked By Antibody | 57434
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Google scholar citation report
Citations : 2275

Journal of Alzheimers Disease & Parkinsonism received 2275 citations as per google scholar report

Journal of Alzheimers Disease & Parkinsonism peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

A Major Early Driver of Tauopathy and Neurodegeneration that is Blocked by Antibody

5th International Conference on Alzheimer’s Disease & Dementia

Shahpasand K, Kondo A, Zhou XZ, and Lu KP

Royan Institute for Stem Cell Biology and Technology, Iran Cancer Research Institute, Boston

ScientificTracks Abstracts: J Alzheimers Dis Parkinsonism

DOI: 10.4172/2161-0460.C1.021

Traumatic brain injury (TBI) is the best-known environmental risk factor for Alzheimer’s disease (AD), whose defining pathologic features include tauopathy made of hyperphosphorylated tau (PHF-tau) and is characterized by acute neurological dysfunction. However, tauopathy is undetectable acutely after TBI and how TBI leads to tauopathy which in turn would increase risk of AD is unknown. Here we identify a neurotoxic cis conformation of phosphorylated tau at Thr231 as a major early driver of TBI and neurodegeneration that is effectively blocked by the conformation specific monoclonal antibody. We found robust cis p-tau after sport- and military-related TBI in humans and mice. Acutely after TBI in mice and stress in vitro, neurons prominently produce cis p-tau, which disrupts axonal microtubule network and transport, spreads to other neurons, and leads to apoptosis, a pathogenic process, which we nominated “cistauosis” that appears long before known tauopathy. Treating TBI mice with cis antibody not only blocks early cistauosis, but also prevents tauopathy development and spread, and restores brain histopathological and functional outcomes. These results uncover cistausosis as an early precursor of tauopathy and an early marker of neurodegeneration after sport and military TBI. We anticipate that cis p-tau will be a new early biomarker and that cis p-tau antibody or vaccines may be used to treat or even prevent TBI, chronic traumatic encephalopathy and AD.

Koorosh Shahpasand has completed his PhD from Tokyo Metropolitan University in 2012, and did his postdoctoral training at Harvard Medical School on the elucitation of cis/trans p-tau conformations during Neurodegeneration; the results of which have been published in Nature. He is now freshly employed assistant professor at Royan Institute and supervising several research projects related to tauopathies. Notably, he has been recently awarded by a prestigous grant from Alzheimer’s Association at Chicago.

Email: [email protected]